Radiopharmaceutical CDMO & Contract Manufacturing Market

Radiopharmaceutical CDMO & Contract Manufacturing Market Report Published

This market screens execution risk through isotope access and logistics reliability rather than installed manufacturing capacity.

Virtue Market Research announces the publication of its latest study on the Radiopharmaceutical CDMO & Contract Manufacturing Market. The key insight is that isotope availability and delivery precision bind production more than facility scale. This matters because missed delivery windows erode clinical timelines and revenue certainty for sponsors and manufacturing partners.

The defining constraint in this market is not plant capacity but the secure and timely access to short-lived isotopes. For decision teams, this shifts diligence toward supply chain resilience and distribution timing rather than headline manufacturing scale. The insight weakens in early-stage development programmes where isotope constraints are less acute and pilot-scale flexibility can offset supply risk.

What the report validates

We confirm that Virtue Market Research has recently published a market research report on the Radiopharmaceutical CDMO & Contract Manufacturing Market. The base year is 2025, with a forecast period of 2026–2030.

Designed for teams underwriting execution risk and revenue durability.
Not written for readers seeking generic sizing pages or vendor shortlists.

The report clarifies which assumptions remain underwriteable, which are regime-sensitive, and which early signals prevent mispricing execution risk.

Market boundary

• What counts: Contract development, manufacturing, and associated services for radiopharmaceuticals, including isotope handling, QC, and time-sensitive distribution.
• What is excluded: In-house pharma manufacturing without third-party engagement and upstream isotope production infrastructure not tied to CDMO services.
• What the scope implies operationally for buyers: Vendor selection depends on isotope sourcing agreements, logistics execution, and regulatory compliance systems.

Structural drivers sustaining demand

• Growth in targeted radiotherapies increases demand for specialised manufacturing, improving revenue certainty for CDMOs aligned with oncology pipelines.
• Short isotope half-lives constrain distribution windows, increasing operating cost exposure for buyers lacking proximity-based manufacturing strategies.
• Regulatory scrutiny on radiopharmaceutical handling raises compliance barriers, improving counterparty stability for established CDMOs.
• Expansion of clinical pipelines drives outsourcing needs, reducing capex sensitivity for biotech firms and improving DSCR headroom.
• Integration of logistics with manufacturing reduces delivery risk, tightening permitting timeline risk for new entrants without distribution networks.

Market segmentation overview

Segmentation is defined as follows:

• By Type: Contract Manufacturing, Contract Development, Analytical Services or Quality Control, Packaging, Labeling and Logistics, Others.

• By Application: Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals, Oncology, Neurology, Cardiology, Others.
• By Region: Global

Dominant segment (why leaders win)

Contract Manufacturing leads the market due to the specialised infrastructure and regulatory approvals required for radiopharmaceutical production. The dominance is structural. High capital intensity and compliance requirements create entry barriers, concentrating capability among a limited number of providers. Vendors with integrated isotope sourcing and validated production workflows reduce execution risk, which stabilises revenue certainty for sponsors.

Secondary or emerging segment (where attention is shifting)

Therapeutic Radiopharmaceuticals are drawing increased attention as clinical pipelines expand beyond diagnostics. This shift is driven by the rise of targeted therapies using alpha and beta emitters. However, these therapies require more complex handling and distribution, increasing execution risk. Decision teams are prioritising partners with proven isotope access and scalable logistics infrastructure.

Recent industry developments

• In June 2025, PharmaLogic Holdings Corp. acquired a majority stake in Agilera Pharma AS, expanding its global radiopharmaceutical development and manufacturing footprint.
• In June 2025, TAG1 Inc. partnered with PharmaLogic to accelerate development of its Pb 212 generator platform, improving access to alpha emitting isotopes.
• In May 2025, Ratio Therapeutics announced plans to build a new radiopharmaceutical R&D and manufacturing facility in Salt Lake City, strengthening internal and contract manufacturing capacity.

About the report

• Market: Radiopharmaceutical CDMO & Contract Manufacturing Market
• Base year: 2025
• Forecast period: 2026–2030
• Market size: USD 2.10 billion in 2025
• Forecast value: USD 3.70 billion by 2030
• CAGR: 12% over 2026–2030
• Segmentation: Type and Application
• Use case: Supports diligence on execution risk, isotope supply constraints, and partner selection in radiopharmaceutical manufacturing